48 related articles for article (PubMed ID: 26157171)
1. Sustained intra-cartilage delivery of interleukin-1 receptor antagonist using cationic peptide and protein-based carriers.
Mehta S; Boyer TL; Akhtar S; He T; Zhang C; Vedadghavami A; Bajpayee AG
Osteoarthritis Cartilage; 2023 Jun; 31(6):780-792. PubMed ID: 36739939
[TBL] [Abstract][Full Text] [Related]
2. DAP1-2: a synthetic peptide targeting IL-1R1 receptor effectively suppresses IL-1β in vitro.
De-Pieri E; Zaccaron RP; Mezzari CG; Cardoso MM; De Roch Casagrande L; Silveira PCL; Machado-de-Ávila RA
Immunol Res; 2024 May; ():. PubMed ID: 38698191
[TBL] [Abstract][Full Text] [Related]
3. Study on the rationality of small diameter metallic airway stent in treatment of tracheal stenosis in injured rabbits.
Li X; Wang C; Liu Z; Wu K; Yang Z; Zeng D; Lin D; Jiang J
J Cardiothorac Surg; 2024 Mar; 19(1):110. PubMed ID: 38443931
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas.
Ding Y; Yi J; Wang J; Sun Z
Heliyon; 2023 Apr; 9(4):e14960. PubMed ID: 37025835
[TBL] [Abstract][Full Text] [Related]
5. Optimization of IL-1RA structure to achieve a smaller protein with a higher affinity to its receptor.
Nouri Barkestani M; Naserian S; Khoddam F; Shamdani S; Bambai B
Sci Rep; 2022 May; 12(1):7483. PubMed ID: 35523814
[TBL] [Abstract][Full Text] [Related]
6. Novel Analgesics with Peripheral Targets.
Ciotu CI; Fischer MJM
Neurotherapeutics; 2020 Jul; 17(3):784-825. PubMed ID: 33063247
[TBL] [Abstract][Full Text] [Related]
7. Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.
Rider P; Carmi Y; Cohen I
Int J Cell Biol; 2016; 2016():9259646. PubMed ID: 28083070
[TBL] [Abstract][Full Text] [Related]
8. Treating inflammation by blocking interleukin-1 in humans.
Dinarello CA; van der Meer JW
Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
[TBL] [Abstract][Full Text] [Related]
9. The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases.
Palomo J; Dietrich D; Martin P; Palmer G; Gabay C
Cytokine; 2015 Nov; 76(1):25-37. PubMed ID: 26185894
[TBL] [Abstract][Full Text] [Related]
10. IL-1 Receptor Antagonist Chimeric Protein: Context-Specific and Inflammation-Restricted Activation.
Rider P; Carmi Y; Yossef R; Guttman O; Eini H; Azam T; Dinarello CA; Lewis EC
J Immunol; 2015 Aug; 195(4):1705-12. PubMed ID: 26157171
[TBL] [Abstract][Full Text] [Related]
11. 5TNF-α and IL-1β neutralization ameliorates angiotensin II-induced cardiac damage in male mice.
Wang Y; Li Y; Wu Y; Jia L; Wang J; Xie B; Hui M; Du J
Endocrinology; 2014 Jul; 155(7):2677-87. PubMed ID: 24877626
[TBL] [Abstract][Full Text] [Related]
12. TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome-associated tissue damage.
Carvalho FA; Aitken JD; Gewirtz AT; Vijay-Kumar M
Mucosal Immunol; 2011 Jan; 4(1):102-11. PubMed ID: 20844479
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic.
Shamji MF; Betre H; Kraus VB; Chen J; Chilkoti A; Pichika R; Masuda K; Setton LA
Arthritis Rheum; 2007 Nov; 56(11):3650-61. PubMed ID: 17968946
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
